This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Sep 2025

World Only Lutein Patented Eyedrop

Lutevisial, CMC and Vitamin E

First worldwide Lutein patented based Eyedrop

OMISAN's ophthalmic formulation is a novel, patented medical device developed for topical use, specifically leveraging the known photoprotective and antioxidant capabilities of the carotenoid Lutein. This development is founded on mitigating the damaging effects of high-energy visible light, particularly the blue-violet spectrum (approximately 390–450 nm), which penetrates the ocular media to reach the retina.

The rationale centers on the pathophysiology of light-induced damage. While the cornea and crystalline lens provide some filtration for UV radiation, high-energy blue light reaches the macula, a region highly susceptible to oxidative insult. The photoreceptor cells, rich in polyunsaturated fatty acids (PUFAs), are vulnerable to photodegradation—a light-induced auto-oxidation process exacerbated by the retina's elevated oxygen consumption. Chronic exposure contributes significantly to the pathogenesis of conditions such as Age-Related Macular Degeneration (AMD) and cataract development.

Lutein is the formulation's key active ingredient, chosen for its intrinsic role as a primary component of the macular pigment. Its therapeutic function is dual-action: acting as a highly effective physical filter to absorb light precisely within the most damaging spectral region (data indicates a high absorption peak between 390 and 450 nm), while simultaneously functioning as a potent antioxidant and radical scavenger. This mechanism bolsters the natural defenses of the ocular tissue against reactive oxygen species. The product employs a proprietary, patented microemulsion technology to ensure stable, biocompatible delivery of Lutein and Vitamin E in minute colloidal particles (0.02μm). Clinically, the formulation is indicated to increase the eye's intrinsic defenses against oxidative stress, offer a critical layer of defense against high-energy light exposure, and provide supplementary ocular lubrication to manage symptoms related to visual fatigue and stress, thereby supporting overall visual well-being.

Mentioned Companies
OMISAN FARMACEUTICI SRL
View company profile